Vir Biotechnology (NASDAQ:VIR) Issues Earnings Results, Beats Estimates By $0.14 EPS

Vir Biotechnology (NASDAQ:VIR) released its earnings results on Wednesday. The company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.14, FiscalAI reports. Vir Biotechnology had a negative return on equity of 53.31% and a negative net margin of 638.88%.The firm had revenue of $238.95 million during the quarter, compared to analysts’ expectations of $135.88 million.

Here are the key takeaways from Vir Biotechnology’s conference call:

• Hepatitis delta efficacy data remained strong: In the 96-week SOLSTICE analysis, 88% of patients receiving elebsiran plus tobevibart achieved undetectable virus versus 53% with tobevibart alone, alongside durable ALT improvements and no treatment-related serious adverse events or discontinuations.
• Vir completed enrollment in all three registrational ECLIPSE studies, with topline data expected from ECLIPSE 1 in the fourth quarter of 2026 and ECLIPSE 2 and 3 in the first quarter of 2027. The company highlighted ECLIPSE 2’s bulevirtide-switch data as a potential launch differentiator.
• The oncology pipeline advanced rapidly following the Astellas collaboration, with VIR-5500 enrolling multiple monotherapy and combination expansion cohorts and potential phase III trials targeted for 2027. Additional data from HER2-targeted VIR-5818 are expected in the second half of 2026.
• Vir ended the quarter with approximately $1.01 billion in cash, cash equivalents, and investments after receiving $315 million from Astellas, extending projected cash runway into the second half of 2028.
• Management acknowledged ongoing senior leadership recruitment, including searches for a new chief medical officer and chief financial officer, while the company continues to manage simultaneous hepatitis delta and oncology development programs.

Vir Biotechnology Stock Down 0.7%

Shares of NASDAQ:VIR traded down $0.06 during midday trading on Wednesday, reaching $9.11. The company had a trading volume of 1,444,865 shares, compared to its average volume of 2,542,792. Vir Biotechnology has a 1-year low of $4.16 and a 1-year high of $11.66. The stock has a market cap of $1.54 billion, a PE ratio of -2.91 and a beta of 1.66. The business’s 50 day moving average price is $9.32 and its 200 day moving average price is $9.00.

Analysts Set New Price Targets

A number of brokerages have recently commented on VIR. Morgan Stanley boosted their price target on Vir Biotechnology from $23.00 to $27.00 and gave the company an “overweight” rating in a report on Thursday, June 11th. Wall Street Zen cut Vir Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Leerink Partners raised their price target on shares of Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.88.

Insider Buying and Selling

In other Vir Biotechnology news, Director Janet Napolitano sold 3,200 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.45, for a total value of $30,240.00. Following the completion of the transaction, the director directly owned 21,216 shares in the company, valued at $200,491.20. This trade represents a 13.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Vir Biotechnology

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new stake in shares of Vir Biotechnology in the 2nd quarter valued at approximately $35,000. UMB Bank n.a. increased its holdings in Vir Biotechnology by 1,418.7% during the fourth quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock worth $43,000 after buying an additional 6,597 shares during the last quarter. Daiwa Securities Group Inc. raised its position in Vir Biotechnology by 2,200.6% during the second quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company’s stock worth $62,000 after acquiring an additional 11,773 shares in the last quarter. DRW Securities LLC bought a new stake in Vir Biotechnology during the fourth quarter worth $72,000. Finally, Aigen Investment Management LP acquired a new stake in Vir Biotechnology in the fourth quarter valued at $76,000. Institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.